Agoracom Blog

The Roundup – @Novamind_Inc $ $NVMDF $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 9:28 AM on Saturday, April 10th, 2021

A weekly summary of Novamind news and media

MULTIMEDIA April 8, 2021

Yaron Conforti on Psychedelic Medicine Today and 10 Years from Now

Novamind’s CEO talks with PsyFi about the future of healthcare and the spectrum of alternative services available today in our clinics.

MULTIMEDIA April 8, 2021

Dr. Reid Robison on How Psychedelic Healing Works and Who Benefits From It

Novamind’s CMO talks with Mark Novak about the potential long-term effects of using psychedelics in a therapeutic setting.

INDUSTRY NEWS April 7, 2021

Bringing New Hope to a State Struggling with Mental Illness

The Daily Utah Chronicle speaks with Novamind’s CMO, Dr. Reid Robison, on the game-changing effects of psychedelic-assisted therapy.

View all media

Could Group Therapy Get A Boost From Psychedelics?

A new psychedelic group therapy trial is set to take place this fall with six veterans who suffer from post-traumatic stress disorder. It’s another example of how researchers are investigating psychedelic-assisted group therapy to help patients connect more deeply and broaden access to the potential medical benefits of psychedelics.

UW-Madison Pioneers Master’s Program in Psychoactive Drugs

The University of Wisconsin–Madison School of Pharmacy is launching a new master’s program on Psychoactive Pharmaceutical Investigation. As the first graduate level, degree-based training program for the study and applications of psychedelics, it marks a significant step toward a more global understanding of these groundbreaking therapies, and a highly trained workforce to administer them.

Follow @novamind_inc on Instagram


For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , ,

Comments are closed.